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Abstract. Obesity, hypertension, dyslipidemia, and insulin resistance have been associated with an increased risk of cognitive
impairment or dementia. Together, these risk factors cluster as metabolic syndrome (MetS). The first aim of this systematic
review was to identify and critically review studies assessing associations between MetS and cognition, with consideration given
both to early cognitive changes and the severe endpoint of dementia. The second aim was to identify and discuss limitations
in the literature and subsequent difficulties in drawing conclusions from research to date. Nine studies that assessed cognitive
performance and ten studies that estimated incidence of dementia in relation to MetS were identified and appraised. Limitations
in the literature include the lack of standardized nomenclature for cognitive variables, the use of multiple MetS definitions, and
the difficulty in differentiating the adverse effects of multiple risk factors on cognition.
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INTRODUCTION19
Cognitive decline and dementia are significant20
health issues given the aging of the world population21
[1]. An emerging literature indicates that metabolic22
syndrome (MetS) is a risk factor for lower cogni-23
tive function and dementia. In the present paper we24
review substantive findings in this literature with a25
focus on important methodological issues surround-26
ing this research. Importantly, we include research27
on cognitive deficit in non-demented individuals in28
our review. We take this approach because poorer
∗Correspondence to: Georgina E. Crichton, Nutritional Physiol-
ogy Research Centre, University of South Australia, GPO Box 2471,
Adelaide, South Australia 5001, Australia. Tel.: +61 8 83021452;
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performance in cognitively normal individuals is one 29
of the most important risk factors for dementia [2, 3] 30
and Alzheimer’s disease (AD) [4]. 31
Several previous reviews have dealt with asso- 32
ciations among specific components of MetS and 33
cognitive functioning. It is clear that individual car- 34
diovascular events and risk factors are associated with 35
lowered cognition and dementia [5]; and a growing 36
research literature suggests that multiple vascular risk 37
factors may have an additive adverse effect on cog- 38
nition, resulting in increased risk for dementia [6–9]. 39
MetS is of concern partly because it represents a 40
clustering of risk factors for morbidity and mortality 41
[10, 11] and partly because these risk factors may inter- 42
act in a synergistic manner to influence cognition in a 43
negative manner. 44
MetS has been defined as a clustering of the fol- 45
lowing risk factors: Central obesity, elevated blood 46
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pressure, dyslipidemia (elevated triglycerides and low-47
ered high-density lipoprotein cholesterol), and insulin48
resistance [12]. The clustering of these specific car-49
diovascular disease (CVD) risk factors is associated50
with an increased risk of developing CVD and diabetes51
[12] as compared with the risk associated with each52
individual risk factor acting alone. MetS is associated53
with an increased risk of stroke [13], and in addition,54
abdominal obesity and MetS are strongly associated55
with elevated concentrations of atherogenic lipopro-56
teins, and therefore increase the risk of coronary heart57
disease [14]. While there is no single known cause58
for MetS, a number of non-modifiable factors includ-59
ing age, genetics, ethnicity, and gender, influence its60
prevalence [15]. Importantly, lifestyle factors, such as61
diet, are a primary contributor to both the development62
and subsequent course of MetS [16].63
GOALS OF THE REVIEW64
One recent review examined nine prospective65
population-based studies which addressed MetS and66
one or more of its individual risk factors for cognitive67
disorders [17]. These authors concluded that MetS is68
highly likely to be associated with cognitive impair-69
ment and vascular dementia (VaD), but not to AD.70
Following from this review and other papers in this71
special issue of the Journal of Alzheimer’s Disease,72
the major objective of the present review is to address73
two methodological challenges in this area of research:74
1) determining which specific cognitive abilities are75
adversely affected by MetS; and 2) separating the role76
of the multiple influence of risk factors specific to MetS77
from the impact of multiple risk factors in general on78
cognition. Given the early stage of this research we79
include both cross-sectional and prospective studies,80
including longitudinal analyses.81
LITERATURE SELECTION82
A search was undertaken on electronic databases83
for studies that examined cognitive functioning asso-84
ciated with MetS, or estimated prevalence or incidence85
of probable dementia associated with MetS. The search86
was limited to studies that reported on MetS as a global87
indicator of vascular risk, and excluded studies that88
examined only one or more of the individual com-89
ponents of the syndrome. MetS had to be diagnosed90
based on having any three of five risk factors (elevated91
waist circumference, elevated triglycerides, reduced92
high-density lipoprotein cholesterol, elevated blood93
pressure, elevated fasting glucose) according to Alberti 94
et al. [12]. Cognitive function studies had to provide 95
measures for at least one aspect of cognition obtained 96
from neuropsychological testing. Publications which 97
used self-reported cognitive function were excluded. 98
Dementia risk studies had to provide an estimate of 99
probable dementia, including AD, VaD, or mild cog- 100
nitive impairment (MCI). Studies were not required 101
to have included brain imaging in their assessment 102
but those which used only single test screening mea- 103
sures as indices of dementia or cognitive function were 104
excluded. If it was unclear whether the paper met 105
the inclusion criteria, the full text was obtained. A 106
total of 19 studies were included in this review. Two 107
papers reported results from the same study, but as they 108
assessed different outcome measures, they were treated 109
as two separate studies for the purpose of this review 110
[18, 19]. 111
The studies included in this review varied greatly 112
in terms of study design and outcome measures. Nine 113
studies used standardized neuropsychological testing 114
to assess cognitive performance as the primary out- 115
come measure. Ten studies used a combination of 116
screening measures, neuropsychological testing, clin- 117
ical evaluations, and brain imaging to make diagnoses 118
of one or a combination of AD, VaD, or MCI. 119
ASSESSMENT OF COGNITION 120
Neuropsychological testing 121
Authors identify the underlying latent variables 122
(cognitive domains) measured by various tests, or test 123
composites, differently. This makes it difficult if not 124
impossible to determine which specific domains of 125
cognitive functioning are affected by MetS and its 126
components. In order to draw conclusions about which 127
cognitive measures are associated with MetS, one must 128
use a standard definition of tests. In this review, we 129
accomplish this objective by what tests measure using 130
Lezak [20], a much recognized authoritative text and 131
taxonomy of measures. 132
The majority of studies assessed at least three differ- 133
ent cognitive abilities. Some studies used a single test 134
as a measure of a particular cognitive ability, while oth- 135
ers used a combination of tests. The two case-control 136
studies [21, 22] conducted the most thorough neu- 137
ropsychological assessments, each one measuring at 138
least six cognitive abilities. The most commonly tested 139
cognitive abilities in terms of the Lezak taxonomy 140
were memory, psychomotor speed, and attention. Ver- 141
bal learning and recall tests were the most frequently 142
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used measure of memory. Verbal fluency and language143
tests were also frequently performed. Processing speed144
was most commonly assessed using letter, symbol or145
digit substitution tasks. Perception and construction146
were assessed less frequently.147
Dementia status measures148
Ten studies determined the likelihood of dementia149
(including AD, VaD, and MCI) associated with MetS.150
All used the National Institute of Neurological and151
Communicative Disorders and Stroke-Alzheimer’s152
Disease and Related Disorders Association (NINCDS-153
ADRDA) work group criteria for a diagnosis. Five154
of the six studies used brain imaging as part of their155
assessment procedure [23–27].156
Assessment of metabolic syndrome157
The Third Adult Treatment Panel of the National158
Cholesterol Education Program (ATP III NCEP) cri-159
teria [16] was used in 13 studies. Five studies used160
this definition but with slight variations. As they still161
required the presence of any three of the five risk fac-162
tors, they were included in the review. Modifications163
made to the ATP III NCEP criteria were higher cut-off164
values for hypertension to adjust for older populations165
[28] and the use of body mass index instead of waist166
circumference as an indicator of abdominal obesity167
[27, 29]. Three studies used slightly altered glucose168
criterion [22, 28, 29]. One study used a modified ver-169
sion of the ATP III NCEP criteria (diabetes defined170
by self-report or medication use) and the European171
Group for the Study of Insulin Resistance (EGIR) cri-172
teria to compare any differences in findings by using173
two definitions which focus on different risk factors174
[30]. As three components of MetS were still required175
for diagnosis, the study was included.176
MAJOR FINDINGS177
Table 1 summarizes all studies that found significant178
associations between MetS and impaired cognitive per-179
formance or dementia. Studies which did not find an180
association between MetS and cognitive performance181
or dementia, or which found negative associations182
between them, are described in Table 2.183
Metabolic syndrome and cognitive performance184
Classifying tests by Lezak [20], MetS was associ-185
ated with significantly poorer cognitive performance in186
four cross-sectional studies [21, 22, 28, 31]. The two 187
cross-sectional case-control studies found that persons 188
with MetS had statistically lower mean levels of perfor- 189
mance in psychomotor speed [21, 22], verbal fluency 190
[21], and arithmetic reasoning [21] than the ‘control’ 191
referent groups. The remaining two cross-sectional 192
studies reported similar findings, with psychomotor 193
speed, verbal memory, perception, attention, concept 194
formation and global cognition negatively associated 195
with MetS [28, 31]. 196
In the one prospective study [32], MetS was associ- 197
ated with a higher risk of poor memory performance at 198
follow up 12 years later. Studies which included longi- 199
tudinal analyses found that MetS was associated with 200
declines in verbal fluency over a 14-year period [33], 201
and with declines in global cognition (assessed by a 202
screening measure) over three years [34]. The find- 203
ings of one longitudinal study [29] were in contrast to 204
the other included studies. Although at 5-year follow- 205
up, there was significant decline in cognitive function 206
(MMSE, processing speed, and verbal memory), the 207
authors reported that those with MetS had ‘decelerated 208
decline’ over this time period [29]. This study was con- 209
ducted in elderly persons between the ages of 85 and 210
90. 211
Metabolic syndrome and dementia risk 212
MetS-related risk for AD was increased significantly 213
in two studies [25, 26], for VaD in two studies [18, 24], 214
and for progression from MCI to dementia in one 215
study [19]. Associations found between MetS and any 216
dementia type (MCI, AD, VaD) in another study [27] 217
did not remain statistically significant with statisti- 218
cal adjustment for education, ethnicity, and depressed 219
mood. In contrast, a significantly lower risk for AD in 220
those aged 75 years or older with MetS was found in 221
one study [35], which adjusted for demographic and 222
cardiovascular factors. 223
Two cross-sectional studies did not find an asso- 224
ciation between dementia and MetS; one did not 225
include any brain imaging in their neuropsychologi- 226
cal assessment [36], and neither adjusted statistically 227
for potential confounding variables [23, 36]. These two 228
studies also had considerably smaller sample sizes than 229
the cross-sectional studies that did find positive associ- 230
ations between MetS and dementia, so may have been 231
insufficiently powered to detect such relationships. 232
One prospective study failed to find an association 233
between the presence of MetS and increased risk for 234
dementia and its main subtypes over four years, in an 235
elderly population [30]. 236
Uncorrected Author Proof
4
G
.E.Crichton
et
al./M
etabolic
Syndro
m
e
a
nd
Cognition
Table 1
Studies finding positive associations between metabolic syndrome and cognitive impairment or dementia
Study n Gender Cognitive abilitiesa or dementia
type (and associated OR/HR,
95% CI) associated with MetS
Single risk factors associated with
impaired cognition/dementia
Adjustments
Cross-sectional
Dik et al. [28]b 1183 M/F Perception & abstract reasoning
(Fluid intelligence)
Psychomotor speed Verbal
memory Global cognition
(Screening test)
Hyperglycemia (psychomotor
speed, perception & abstract
reasoning, verbal memory,
screening test) Low HDL
cholesterol (psychomotor
speed, perception & abstract
reasoning)
Age, gender, education, smoking,
alcohol; diabetics excluded
Cavalier et al. [31]b 819 M/F In men: Verbal memory
Attention, concept formation
(screening test)
Not examined Age, gender, education,
depressed mood, coronary
heart disease
Vanhanen et al. [26]b 959 M/F AD (OR 2.71, 95% CI 1.44–5.10) In women: Low HDL cholesterol,
high fasting glucose associated
with AD prevalence
Age, education, ApoE4 genotype,
total cholesterol, diabetes
Cross-sectional: Case-control
Segura et al. [21]b 55 MetS, 35 controls M/F Psychomotor speed Verbal
fluency Arithmetic reasoning
(Working memory/executive
function)
Not examined Education, gender,
van den Berg et al. [22]b 83 MetS, 64 DM2, 100
controls M/F
Attention (Information
processing speedc, Executive
functionc) Psychomotor speedc
Verbal fluency (Executive
function)c
None Age, gender, estimated IQ
Razay et al. [25]b 50 AD, 75 controls M/F AD (OR 3.20, 95% CI 1.20–8.40) Elevated triglycerides,
hyperglycemia, low HDL
cholesterol (in those with AD
compared with controls).
Hypertension associated with
decreased risk of AD
Age, gender, location (controls:
Similar age range, no memory
complaints, normal scores on
MMSE); diaetic treatment
excluded
Prospective
Komulainen et al. [32]b 101 F Verbal memory Low HDL cholesterol (memory) Age, education, depression
Reffaitin et al. [24]b 7087 M/F VaD (HR 2.44, 95% CI
1.25–4.77)
High triglycerides at baseline
associated with increased risk
of all-cause dementia & VaD
risk Diabetes significantly
associated with increased risk
of all-cause dementia & VaD
Age, gender, education, city
center, ApoE4 genotype
(continued next page)
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Table 1 (continued)
Study n Gender Cognitive abilitiesa or dementia
type (and associated OR/HR,
95% CI) associated with MetS
Single risk factors associated with
impaired cognition/dementia
Adjustments
Yaffe et al. [34]b 4895 F Cognitive impairment (OR 1.66,
95% CI 1.14–2.41)
Multivariate: No longer
significant. 17% increase in
risk of impairment per unit
increase in number of MetS
components. High glucose
significantly associated with
cognitive impairment
Age, race, depressed, mood,
education
Solfrizzi et al. [18] 2097 M/F VaD (HR 3.71, 95% CI
1.40–9.83)
Risk increased when subjects
with baseline under- nutrition
excluded; risk increased for
inflammation. No individual
MetS component associated
with dementia risk
Age, gender, education, alcohol,
smoking, fibrinogen, non-high
density lipoprotein cholesterol,
ratio of ApoB to ApoA-I,
coronary artery disease, stroke
Solfrizzi et al. [18] 2097 M/F VaD (HR 3.71, 95% CI
1.40–9.83)
Risk increased when subjects
with baseline under- nutrition
excluded; risk increased for
subjects with MetS & high
inflammation. No individual
MetS component associated
with dementia risk
Age, gender, education, alcohol,
smoking, fibrinogen, non-high
density lipoprotein cholesterol,
ratio of ApoB to ApoA-I,
coronary artery disease, stroke
Longitudinal
Van den Berg et al. [29]b 562 M/F Global cognition (screening test)d
Psychomotor speedd attentiond
Elevated fasting glucose
(screening test)d BMI
(screening test)d
Gender, education
Yaffe et al. [34]b 1624 M/F Global cognition (screening test) Elevated fasting glucose (verbal
memory)
Age, gender, education, birth
place, depression, smoking,
alcohol, MI
Knopman et al. [33]b 1130 M/F Verbal fluency Hypertension (verbal fluency)
Diabetes (psychomotor speed)
Age, gender, religion, education
Abbreviations: AD = Alzheimer’s disease; Apo = apolipoprotein; BMI = body mass index; CI = confidence interval; DM2 = type 2 diabetes mellitus; F = female; HDL = high-density lipoprotein;
HR = hazard ratio; M = male; MCI = mild cognitive impairment; MetS = metabolic syndrome; MI = myocardial infarct; MMSE = Mini-Mental State Examination; OR = odds ratio; VaD = vascular
dementia.
aAbilities as defined by Lezak [20]; Ability in parentheses represents ability as described by author(s) if differs from Lezak. bSignificant after full adjustment; cTests grouped together as z-scores;
dAssociated with decelerated cognitive decline.
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Table 2
Studies finding negative or no associations between metabolic syndrome and cognitive impairment or dementia
Study n Gender Cognitive abilities or dementia
type assessed
Associatio with MetS Single risk factors associated with
impaired cognition/dementia
Adjustments
Cross-sectional
Gatto et al. [38]a 853 M/F Executive function, verbal
learning, logical memory,
visual episodic memory,
semantic memory, global
cognition
Nil Hypertension (verbal learning,
semantic memory, global
cognition/sum of scores).
Age, gender, ethnicity, education,
income, study, depression,
medications
Isik et al. [23] 267 M/F AD, VaD, MCI Nil Insulin resistance - no significant
difference between those with
and without cognitive
impairment.
Nil; diabetics excluded
Choi et al. [36] 175 M/F Probable AD, MCI Nil No MetS components associated
with probable AD or MCI.
Depression significantly
associated with AD prevalence.
Nil
Prospective
Muller et al. [30] 2476 M/F All-cause dementia, AD, DAS Nil (using NCEP - ATP III or
EGIR criteria)
Diabetes & hyperinsulinemia
significantly associated with
increased risk for incident AD,
DAS, and overall dementia.
Age, gender, education, ethnicity,
ApoE4 genotype, smoking,
cohort
Forti et al. [35] 749 M/F Dementia, AD, VaD In those 75 y or older: MetS
associated with a lower risk of
AD (HR 0.33, 95% CI
0.12–0.94)
Abdominal obesity significantly
associated with lower risk of
overall dementia.
Age, gender, education, ApoE4
genotype, physical activity,
CVD, stroke, inflammation
status, hyperhomocysteinemia
Abbreviations: AD = Alzheimer’s disease; Apo = apolipoprotein; CI = confidence interval; CVD = cardiovascular disease; DAS = dementia associated with stroke; EGIR = European Group for the
Study of Insulin Resistance; F = female; HR = hazard ratio; M = male; MetS = metabolic syndrome; MCI = mild cognitive impairment; NCEP-ATP III = National Cholesterol Education Program
Adult Treatment Program III; VaD = vascular dementia; y = years.
aFive cognitive domains determined by factor analysis of 14 cognitive tests.
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The majority of studies adjusted their statistical237
analyses for the effects of age, gender, and educa-238
tion. Four studies took into account individual vascular239
risk factors [18, 19, 26, 35] and four adjusted for240
apolipoprotein E4 genotype [24, 26, 30, 35].241
SUMMARY OF MAIN FINDINGS242
For cognitive function measured by neuropsycho-243
logical testing, detriments in psychomotor speed,244
verbal memory and fluency, and attention were the245
abilities most frequently associated with MetS using246
standard definitions of what tests measure by Lezak247
[20]. However, these abilities were also those most248
frequently assessed. Using definitions of cognitive249
abilities as defined by authors, decrements in executive250
function (as well as information processing speed and251
verbal memory) were most frequently reported [21, 22,252
28, 31–34]. In addition, having MetS was associated253
with AD [25, 26] cross-sectionally, with increased risk254
for VaD over 3.5 to 4 years [18, 24], and with increased255
risk of progression from MCI to dementia over the256
same time period [19]. In populations over the age of257
75, having MetS was associated with a lower risk of258
AD [35], and with decelerated cognitive decline [29].259
METHODOLOGICAL ISSUES260
The ability to determine the specific cognitive abil-261
ities most influenced by MetS is difficult. Firstly, the262
broad range of cognitive measures affected by MetS,263
may reflect its diffuse effects on the brain function264
and structure. There was evidence for global effects265
on cognition in those that used global screening mea-266
sures of cognition [28, 34]. Further, it is well known267
that clinical tests are not pure measures of what they268
purport to measure and are influenced by task diffi-269
culty [37]. Absence of test purity was evidenced by270
the wide-ranging nomenclature used to classify neu-271
ropsychological tests. In part this is due to the fact that272
many clinical tests measure more than one aspect of273
cognition, and correlate highly with each other.274
The frequently used Stroop Color-Word Test and275
Trail Making Tests A and B are examples of tests that276
are commonly classified as tests of executive func-277
tion [21, 22, 31, 38]. Executive function is extremely278
difficult to separate from general fluid intelligence,279
evidenced by the literature attempting to determine280
relationships between the two [39–42], and from mem-281
ory and attention [43]. The terms executive function282
or fluid intelligence are often used for tests measuring283
more defined abilities such as verbal fluency, arithmetic 284
reasoning, abstract reasoning, and attention. The use 285
of these terms interchangeably can therefore make it 286
difficult to 1) directly compare findings, and 2) draw 287
conclusions from them. In depth considerations of the 288
executive function construct indicate that it is often 289
used uncritically in the literature [37] and executive 290
function is often used synonymously with frontal lobe 291
function, an inappropriate practice [44]. Adding to the 292
problem of test impurity is the fact that tests that mea- 293
sure different cognitive constructs are often not always 294
of the same difficulty level. 295
There are two possibilities that may help to solve 296
these problems in the future. The use of factor anal- 297
ysis to form constellations of theoretically relevant 298
cognitive domains [45], and the use of highly precise 299
laboratory information processing tasks on single cog- 300
nitive constructs [46], have both been recommended 301
but have not been widely accepted at this point in 302
time. Defining cognitive domains can be improved by 303
using multiple individual tests that measure the same 304
latent construct, and using factor analytic techniques 305
to extract theoretically relevant variables from compre- 306
hensive neuropsychological test batteries [47]. These 307
recommendations present two options for improving 308
test purity. 309
The second major challenge in this literature is the 310
difficulty in determining the effect that specific single 311
risk factors and combinations of multiple risk fac- 312
tors are having on cognition. Of the 19 studies in 313
this review, 17 examined associations between the 314
various components of MetS and cognitive perfor- 315
mance. Hyperglycemia or diabetes were associated 316
with poorer cognitive performance [28], cognitive 317
decline [27, 33, 34], with prevalent AD [25, 26], or 318
future likelihood of developing dementia [24]. Both 319
diabetes and hyperinsulinemia were related to higher 320
risk for AD and dementia associated with stroke in one 321
study [30]. 322
Other investigators reported no significant differ- 323
ence in insulin resistance between those with and 324
without cognitive impairment [23], or that associations 325
between the syndrome and poor cognition remained 326
with the exclusion of diabetics [26, 38]. The Hoorn 327
study [22], comparing cognitive function in individ- 328
uals with MetS without type 2 diabetes, individuals 329
with type 2 diabetes, and control subjects (without 330
diabetes and no more than one MetS component) 331
found similar associations with cognition for those 332
with MetS and those with type 2 diabetes. However, 333
analyses of associations between the five individual 334
MetS components with cognitive performance failed 335
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to find any significant relationships. Other components336
of MetS such as low high-density lipoprotein choles-337
terol, elevated triglycerides, and hypertension have338
been associated with poorer cognitive performance339
[28, 32, 33, 38], dementia [24–26], or progression from340
MCI to dementia [19], and yet there are studies indicat-341
ing that lower levels of total cholesterol are detrimental342
to cognitive performance [48–50]. Further investiga-343
tion, taking into account the precise levels of variables344
such as blood pressure and cholesterol, may improve345
our understanding about whether or not these compo-346
nents of MetS are positive or negative risk factors for347
cognitive performance.348
Nevertheless, there is evidence that MetS as a whole349
has a detrimental influence on cognition and that the350
relationship between MetS and cognition are not sim-351
ply driven by one predominant component of the352
syndrome. In a study speaking directly to this issue,353
Gatto and colleague [38] found a relationship between354
the number of MetS components and cognitive func-355
tion, with global cognition and semantic memory356
scores significantly decreasing with each addition of357
a MetS component. Cavalier et al. [31] found that an358
increasing number of MetS components was associ-359
ated with progressively worse cognitive performance360
in men. These findings are supported by those of Yaffe361
and colleagues [27] who found a 17% increase in the362
risk of impairment per unit increase in the number of363
MetS components. Similarly, Komulainen et al. [32]364
found no significant interactions between single risk365
factors (blood pressure, glucose levels, or waist cir-366
cumference) with memory function, but women with367
MetS had a four-times higher risk of poor memory than368
those without, and, most importantly, increasing the369
number of MetS components served to further increase370
the risk. Finally, Solfrizzi et al. [18] found the risk371
of VaD due to MetS was about four and a half times372
higher than the additive risk of its individual compo-373
nents. The design of these studies is exemplary with374
regard to how the issue of relations between MetS and375
cognition should be approached.376
It is important for investigators to take the steps377
necessary to determine if the MetS relationship to cog-378
nition is simply driven by one or more major risk379
factors such as obesity or diabetes, compared to the380
impact of MetS per se. It is clear that any combina-381
tion of multiple risk factors, regardless of whether they382
are components of MetS, predict cognition better than383
a single risk factor [5, 51]. However at this point in384
MetS research, it is not known whether it is the specific385
MetS risk factors that are affecting cognitive func-386
tion adversely, or if multiple risk factors of any kind387
have this effect. Consequently, one of the challenges 388
in future research will be to differentiate between the 389
cumulative negative impact on cognition of risk fac- 390
tors specific to MetS and the generally adverse effect 391
of multiple risk factors, including non-metabolic fac- 392
tors and any other combination of CVD risk factors. 393
Using statistical methods [52] to measure the weights 394
for components of a composite variable, and there- 395
fore which component is driving the results, will be 396
needed. Secondly, in order to make this distinction, it is 397
important to use standardized MetS criteria, requiring 398
measures of abdominal obesity (waist circumference), 399
high-density lipoprotein cholesterol, fasting plasma 400
glucose, triglycerides, and blood pressure with cut-offs 401
as defined by the recent joint statement from the Inter- 402
national Diabetes Federation, National Heart, Lung, 403
and Blood Institute, and American Heart Association 404
[12]. 405
Finally, a number of potential biases in this litera- 406
ture must be considered. Survival bias may play a role 407
in any health study conducted in very elderly popula- 408
tions. Van den Berg and colleagues [29] acknowledge 409
that a ‘survivor effect’ may explain their findings of 410
decelerated cognitive decline in individuals between 411
the ages of 85 and 90 years. As noted by these authors, 412
participants who have reached the age of 85 and are 413
able to take part in cognitive and health research may 414
be less susceptible to health problems [29]. Forti et al. 415
[35] make similar conclusions with regard to their find- 416
ing of an association between MetS and lowered risk 417
for AD in persons aged over 75 years. Muller and col- 418
leagues [30] similarly offer survival bias as a potential 419
explanation for the lack of associations found between 420
dementia and MetS in an elderly cohort (mean age 421
of 76 years). Interestingly, the studies that found no 422
association between MetS and dementia risk were all 423
conducted in samples aged at least 60 years [23, 30, 424
36]. As the effect of risk factors on cognition may 425
change with increasing age [22] and consequently for 426
survivors, it is essential that age be considered as a 427
potential effect modifier and that changes in risk fac- 428
tors and cognitive function over time be considered 429
concurrently. 430
There are other more obvious needs for methodolog- 431
ical improvement in studies. The majority of studies 432
(63%) reviewed here [18, 19, 24, 27, 28, 30–35, 433
38] did make statistical adjustments for age, gen- 434
der, and education. Fewer studies (47%) took into 435
account other cardiovascular factors, socio-economic, 436
or lifestyle variables (e.g., activity level, physical exer- 437
cise, depressed mood, personality characteristics), that 438
impact upon cognition [18, 19, 26, 28, 30, 31, 34, 439
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35, 38] (see Tables 2 and 3). That effect sizes were440
reduced in some studies when confounders such as441
age, low education, low total cholesterol, and ApoE4442
phenotype were adjusted statistically for [26] demon-443
strates the need to control for potential confounders.444
Adjusting for confounders may also reveal stronger445
relations between MetS and cognitive outcomes; Sol-446
frizzi and colleagues [18] demonstrated an increased447
risk for VaD when baseline nutrition and inflammation448
status were taken into consideration.449
POSSIBLE MECHANISMS FOR450
METS-COGNITION RELATIONS451
Typically, exploring the underlying mechanisms for452
relations between MetS and cognition has involved453
considering the individual pathophysiological effects454
on the brain from each individual component of the455
syndrome. As recognized by Frisardi and colleagues456
[53], this view may be reductive to explain the appar-457
ent global effects on cognitive decline. Consequently,458
‘metabolic-cognitive syndrome’ (MCS; MetS plus459
cognitive impairment of degenerative or vascular ori-460
gin) has been proposed as a pathophysiological model461
to explain the complex relationship between metabolic462
disorders, cognitive disturbances, and pathological463
condition [54]. The mechanisms linking MetS with464
age-related cognitive decline, MCI, dementia, and AD,465
are discussed in detail in an excellent review by Fris-466
ardi et al. [53], integrating the individual components467
of MetS and their influence on cognitive decline. The468
identification of a clinical profile of MCS, as developed469
by these authors, will be important for future identifi-470
cation of persons at higher risk of developing cognitive471
impairment.472
CONCLUSION473
Despite the small number of studies, widespread474
variations in study design and assessment of cogni-475
tion, the results of this review suggest that the presence476
of MetS increases the risk of poor performance cogni-477
tively, and of cognitive impairment in an absolute sense478
(MCI or dementia). Using conventional and relatively479
standardized definitions of various tests, the strongest480
evidence for MetS related deficits prior to dementia is481
for information processing speed, verbal memory, and482
attention.483
This review has hopefully raised awareness of sev-484
eral issues of importance in MetS-cognition research.485
Not enough evidence with multiple test batteries is486
available to determine whether these results do not 487
merely reflect a diffuse influence of MetS on global 488
cognition [28, 34] rather than on specific abilities. The 489
use of more comprehensive test batteries and factor 490
analysis applied with an emphasis on theory and empir- 491
ical relations among variables is recommended. It is 492
extremely important to deal with this issue in future 493
studies as it is important to know if, as recent research 494
suggested, specific patters of cognitive deficit predict 495
decline from normal cognition to MCI and from MCI 496
to different forms of dementia [55, 56]. 497
Finally it is important in future research to have stud- 498
ies that accomplish what should be two major goals in 499
MetS research: 1) To determine whether MetS rela- 500
tions to cognition simply reflect the effects of one or 501
two dominant MetS components, e.g., diabetes, hyper- 502
tension, and obesity, rather than a synergistic effect 503
of multiple MetS components; and 2) to separate the 504
impact of multiple risk factors of any kind on cogni- 505
tion from the impact of multiple risk factors specific 506
to MetS. This is needed to improve our understanding 507
of what is driving the results between poorer cognition 508
and the syndrome, and how brain function is being 509
affected.
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